Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50
years has increased, which is referred to as early-onset CRC or young-onset CRC (YO …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

Immune checkpoint blockade therapy with anti-PD-1 monoclonal antibody (mAb) is a
treatment for colorectal cancer (CRC). However, some patients remain unresponsive to PD …

Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …

Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …

Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …